General Atlantic L.P. Has $8.46 Million Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN)

General Atlantic L.P. decreased its position in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 6.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,695,327 shares of the company’s stock after selling 194,341 shares during the period. Acelyrin comprises 0.3% of General Atlantic L.P.’s portfolio, making the stock its 13th biggest position. General Atlantic L.P.’s holdings in Acelyrin were worth $8,463,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. HighTower Advisors LLC bought a new stake in shares of Acelyrin during the third quarter valued at approximately $50,000. Virtu Financial LLC bought a new stake in shares of Acelyrin during the third quarter valued at approximately $50,000. Intech Investment Management LLC bought a new position in Acelyrin in the third quarter valued at approximately $77,000. US Bancorp DE boosted its stake in Acelyrin by 77.1% in the third quarter. US Bancorp DE now owns 16,854 shares of the company’s stock valued at $83,000 after acquiring an additional 7,336 shares during the last quarter. Finally, Virtus Investment Advisers Inc. bought a new position in Acelyrin in the third quarter valued at approximately $176,000. Institutional investors and hedge funds own 87.31% of the company’s stock.

Wall Street Analyst Weigh In

SLRN has been the topic of a number of recent research reports. Wells Fargo & Company reduced their price objective on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. HC Wainwright reduced their price target on shares of Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Finally, Citigroup dropped their price objective on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $9.60.

Acelyrin Stock Down 1.5 %

NASDAQ SLRN opened at $2.61 on Tuesday. The company has a market capitalization of $261.85 million, a P/E ratio of -1.06 and a beta of 1.27. Acelyrin, Inc. has a 12-month low of $1.85 and a 12-month high of $8.59. The firm has a 50-day moving average price of $2.30 and a two-hundred day moving average price of $3.94.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.